Basiliximab: Clinical Trials

29 trials of Basiliximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 6 unknown, 4 terminated. 29 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 429Completed 19, Unknown 6, Terminated 4

Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab

Trials (filtered) newest first · largest first

All 29 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
Basiliximab, Vedolizumab - Safety and Efficacy
Phase 4UnknownThe First Affiliated Hospital of Soochow University452022-08-012023-10-04
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) - Kidney Transplantation, Kidney Transplant Rejection
Phase 4TerminatedUniversity of Southern California202021-11-232025-11-10
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
Basiliximab 20 MG - Asses Immunosuppression Modulation on Renal Recovery Post LT
Phase 4CompletedFady M Kaldas, M.D., F.A.C.S.712021-01-152025-12-16
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Ruxolitinib - Safety and Efficacy
Phase 4UnknownThe First Affiliated Hospital of Soochow University502020-12-152021-08-25
Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients
Basiliximab 20 milligram [Simulect], Normal Saline - Kidney Transplantation
Phase 4UnknownKing Faisal Specialist Hospital & Research Center1402020-09-012021-02-18
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
Mycophenolate mofetil 500mg Tab. or 250mg Cap., Tacrolimus, Methylprednisolone/prednisolone - Kidney Transplant
Phase 4CompletedChong Kun Dang Pharmaceutical1692018-03-312024-05-22
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Antithymocyte Immunoglobulin (Rabbit), Interleukin 2 Receptor Antagonist - Kidney Transplant Rejection
Phase 4UnknownUniversity of Khartoum3002018-03-212019-01-03
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
Busulfan, Cyclophosphamide, Fludarabine - Thalassemia Major
Phase 4UnknownFirst Affiliated Hospital of Guangxi Medical University302017-04-012017-05-31
Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
Basiliximab, Thymoglobulin - Kidney Transplant Rejection, Kidney Transplant; Complications
Phase 4CompletedCoordinación de Investigación en Salud, Mexico1002016-12-012019-11-15
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
Basiliximab,, Tacrolimus, Methotrexate - Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)
Phase 4CompletedZhongming Zhang2052015-04-012025-06-18
Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
sirolimus, tacrolimus, mycophenolate - Disorder Related to Renal Transplantation, Cytomegalovirus Infections
Phase 4CompletedAssociação Médico Espírita de Botucatu482014-01-012016-02-17
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
Induction therapy, Corticosteroids, EVR+rCNI - End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Phase 4CompletedNovartis Pharmaceuticals20372013-12-032019-01-30
Simulect Versus ATG in Sensitized Renal Transplant Patient
Simulect, ATG Fresenius - Renal Transplant Rejection
Phase 4CompletedUniversity Hospital, Toulouse602013-09-012026-04-08
A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids
Advagraf, Mycophenolate Mofetil, Simulect - Kidney Transplantation
Phase 4CompletedAstellas Pharma Inc11662011-01-222024-11-01
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
ATG-F, Simulect - Glomerulonephritis, IgAN
Phase 4TerminatedCentre Hospitalier Universitaire de Saint Etienne1172011-01-082021-01-20
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
Basiliximab, Tacrolimus, Mycophenolic Acid - Liver Transplantation
Phase 4CompletedUniversity of California, Los Angeles592011-01-012022-09-29
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization - Diabetes Mellitus, Adult-Onset
Phase 4TerminatedArmando Torres Ramírez1342010-02-012024-10-22
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
Everolimus, Tacrolimus (FK506), Basiliximab - Chronic Renal Failure
Phase 4CompletedNovartis Pharmaceuticals362009-12-012014-08-15
Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
Basiliximab, Enteric Coated Mycophenolic Acid (MPA), RAD001 - Renal Transplantation
Phase 4TerminatedNovartis Pharmaceuticals2072009-07-012014-06-06
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
cyclosporine, Everolimus - Renal Transplantation
Phase 4UnknownUniversity Hospital, Antwerp1522008-10-012009-05-18

Showing 20 of 29. Sign in to see all of them.

Conditions studied

Kidney Failure, Chronic (2)  ·  Rejection, Psychology (2)  ·  Renal Insufficiency (2)  ·  beta-Thalassemia (2)  ·  Cytomegalovirus Infections (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Glomerulonephritis (1)  ·  Graft vs Host Disease (1)  ·  Liver Cirrhosis (1)  ·  Neoplasms (1)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Novartis Pharmaceuticals (5)  ·  Astellas Pharma Inc (3)  ·  Novartis (3)  ·  The First Affiliated Hospital of Soochow University (2)  ·  Armando Torres Ramírez (1)  ·  Associação Médico Espírita de Botucatu (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Chong Kun Dang Pharmaceutical (1)  ·  Coordinación de Investigación en Salud, Mexico (1)  ·  Fady M Kaldas, M.D., F.A.C.S. (1)  ·  First Affiliated Hospital of Guangxi Medical University (1)  ·  King Faisal Specialist Hospital & Research Center (1)  ·  Thomas Jefferson University (1)  ·  University Hospital Freiburg (1)  ·  University Hospital, Antwerp (1)

Countries

Switzerland (6)  ·  United States (6)  ·  France (5)  ·  Germany (5)  ·  Belgium (4)  ·  China (4)  ·  Norway (4)  ·  Spain (4)  ·  Sweden (4)  ·  Czechia (3)  ·  Italy (3)  ·  Mexico (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Portugal (3)

Top investigators

Fady M Kaldas, MD (2)  ·  Xuefeng He, doctor (2)  ·  Armando Torres, PhD (1)  ·  Carlo Gerardo B Ramirez, M.D. (1)  ·  Chang-Kwan Oh, Ph.D (1)  ·  Christian Hugo, Prof. Dr. (1)  ·  Gustavo Martinez-Mier, MD (1)  ·  Jean-Louis Bosmans, MD/PhD (1)  ·  Nassim Kamar, MD PhD (1)  ·  Oliver Thomusch, Prof. Dr. (1)  ·  Santhi Voora, MD (1)

Results publications

PMID 16273116, PMID 16699456, PMID 16737942, PMID 17093248, PMID 18322043, PMID 22471345, PMID 22850297, PMID 27547871, PMID 27871759, PMID 29149958, PMID 29752413, PMID 31029086, PMID 31152476, PMID 31536556, PMID 32633157, PMID 32775820, PMID 33277746, PMID 34216395, PMID 34620664, PMID 37253803, PMID 37391381, PMID 39382091

NIH funding

2008 (1), 2009 (1)